Elsevier,
Neuropharmacology, Volume 259, 15 November 2024
This review explores using nanotechnology to enhance the delivery of neuroprotective phytochemicals from medicinal plants for Alzheimer's disease (AD), addressing issues of bioavailability, solubility, and blood-brain barrier penetration, and highlights the potential of nanocarriers to revolutionize neuroprotective drug delivery and improve patient outcomes.
Elsevier,
Brain Research, Volume 1843, 15 November 2024
This study developed a novel mouse model with tamoxifen-inducible knockout of the Gnpat gene, enabling late-onset plasmalogen deficiency to investigate its role in Alzheimer's disease. The model exhibited significant plasmalogen reduction and associated behavioral and nerve function changes, providing a valuable tool for future research on plasmalogen involvement in neurodegeneration and potential therapies.
Elsevier,
Brain Research, Volume 1841, 15 October 2024
This study found that female 5XFAD mice exhibit early impairments in prefrontal-dependent cognitive functions and increased activity of prefrontal PV neurons, unlike their male counterparts. These findings suggest a potential mechanism for the higher risk of Alzheimer's disease in women, highlighting sex-specific early deregulation in the prefrontal cortex.
Elsevier,
Journal of Ethnopharmacology, Volume 333, 28 October 2024
This review investigates the connection between Type 2 Diabetes Mellitus and Alzheimer's disease, focusing on common mechanisms and the potential of traditional Indian herbs to manage both conditions. It also addresses the challenges and innovative strategies in delivering herbal formulations.
Elsevier,
Pharmacological Research, Volume 208, October 2024
The study explores the use of a novel gene delivery system, AAV-aMTD-Parkin, to enhance motor and cognitive functions in animal models of Parkinson’s and Alzheimer’s diseases. This system improves the delivery efficiency of therapeutic proteins, potentially offering a new treatment approach for these neurodegenerative disorders.
Elsevier,
The Lancet Regional Health - Americas, Volume 37, September 2024
This paper supports SDG 3 with evidence of disparate effects of phased COVID-19 vaccine rollout on mental health across US populations, underlining the need for careful planning in future strategies for phased disease prevention and interventions.